The University of Pittsburgh Alzheimer's Disease Research Center (PITT-ADRC) has shown a clear scientific evolution over the past three decades. Since our inception, we have advanced the areas of AD neuropsychiatry, the natural history of AD, validation of clinical criteria, and clinico-pathological correlations. We have pioneered new positron emission technology (PET) techniques for amyloid imaging. We have used a multidisciplinary approach to better understand the transition from normalcy to dementia, have explored the biology of more aggressive forms of AD characterized by psychosis, and have made and contributed to new insights in genetics. This solid scientific background has allowed the PITT-ADRC to develop areas of excellence, which will serve as the basis for the future of the Center. These are reflected in the Center's cores and projects, and most notably in the large number of studies we support in Pittsburgh and at the national and international level. Equally important, the availability of a rich, multidisciplinary training environment along with dedicated, skilled mentoring creates the ?perfect laboratory? to develop and advance young investigators. With our Projects, we are committed to remain at the forefront of the scientific efforts to understand the pathological processes involved in the etiology of AD. Project-1 takes a comprehensive neuroimaging approach to studying subjective cognitive decline (in the context of personality factors), with a focus on amyloid PET imaging as the putative earliest indicator of AD pathology. Project-2 will combine amyloid PET and a measure of synaptic density (11C- UCB-J) to examine pathological status of cognitively normal control subjects who are amyloid- negative but already show hypometabolism or hippocampal atrophy. Project 3 will examine the pathological basis of psychotic symptoms in AD patients, which have a tremendous effect on the quality of life of the patients and their families, and are risk factors for rapid clinical progression of the disease and mortality. The PITT-ADRC, through its pilot projects, engages and involves as many clinical and basic researchers as possible. This extends to all aspects of research relevant to AD and related dementias. The goal of this Revision application is to augment the acquisition of brain imaging data (both MRI and PET), standardize the analysis of all imaging data acquired from ADRC participants, and to make these data available to ADRC investigators, collaborators, and large data repositories (e.g., NACC, ENIGMA) for further analysis.

Public Health Relevance

The University of Pittsburgh Alzheimer's Disease Research Center (PITT-ADRC) aims to be a focal point of innovative research on the cause and effective treatment of Alzheimer's disease (AD). While serving as a local resource for outreach, education and support to patients and caregivers at all stages of the disease, we focus our research efforts on the transition from normal aging into the earliest detectable stages of cognitive decline and have pioneered transformative amyloid imaging technology to facilitate these efforts here and around the world. At the PITT-ADRC, we strive to accomplish our goal through: 1) our own research; 2) involving affiliated investigators at the University of Pittsburgh and nearby institutions in both clinical and basic research; 3) collaborations with other members of the Centers Program; and 4) collaborations with other national and international centers of excellence in AD. The purpose of this Revision of our NeuroImaging Core is to expand the brain imaging data and the data analysis capabilities of the Core to meet the needs of the Center for the next 5-10 years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG005133-35S1
Application #
9416305
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
1997-05-01
Project End
2020-03-31
Budget Start
2018-08-15
Budget End
2019-03-31
Support Year
35
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Minhas, Davneet S; Price, Julie C; Laymon, Charles M et al. (2018) Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A? load. Neuroimage Clin 19:182-189
Mukherjee, Shubhabrata; Mez, Jesse; Trittschuh, Emily H et al. (2018) Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. Mol Psychiatry :
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Hu, Ziheng; Wang, Lirong; Ma, Shifan et al. (2018) Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y) 4:542-555
Brainstorm Consortium (see original citation for additional authors) (2018) Analysis of shared heritability in common disorders of the brain. Science 360:
Koch, Manja; DeKosky, Steven T; Fitzpatrick, Annette L et al. (2018) Apolipoproteins and Alzheimer's pathophysiology. Alzheimers Dement (Amst) 10:545-553
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :

Showing the most recent 10 out of 667 publications